Jonathan Allan - 15 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role: GENERAL COUNSEL & CORP SEC
Signature: /s/ Jonathan Allan
Issuer symbol: STOK
Transactions as of: 15 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 17:23:45 UTC
Previous filing: 19 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Allan Jonathan	GENERAL COUNSEL & CORP SEC	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD	/s/ Jonathan Allan	17 Mar 2026	0001966716

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STOK	Common Stock	Options Exercise		+7,475	+61%	$0.000000^*	19,731	15 Mar 2026	Direct	F1
transaction	STOK	Common Stock	Options Exercise		+6,000	+30%	$0.000000^*	25,731	15 Mar 2026	Direct
transaction	STOK	Common Stock	Options Exercise		+12,000	+47%	$0.000000^*	37,731	15 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STOK	Restricted Stock Units	Options Exercise		-7,475	-50%	$0.000000^*	7,475	15 Mar 2026	Common Stock	7,475		Direct	F2, F3
transaction	STOK	Restricted Stock Units	Options Exercise		-6,000	-33%	$0.000000^*	12,000	15 Mar 2026	Common Stock	6,000		Direct	F2, F4
transaction	STOK	Restricted Stock Units	Options Exercise		-12,000	-25%	$0.000000^*	36,000	15 Mar 2026	Common Stock	12,000		Direct	F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3	The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
F4	The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.
F5	The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.